Etopa Injection
Etoposide
Getwell Pharmaceuticals
| Pack size | |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price |
Indications
Etopa Injection is used for:
Lung cancer, Testicular cancer
Adult Dose
Intravenous
Testicular Cancer
50-100 mg/m²/day IV on days 1-5, OR
100 mg/m²/day IV on days 1, 3, 5
Repeat q3-4week
Small-Cell Lung Cancer
35 mg/m²/day IV for 4 days, OR
50 mg/m²/day IV for 5 days; repeat q3-4week
Oral
Small cell lung cancer
Adult: Twice the IV dose, rounded to the nearest 50 mg.
Child Dose
Renal Dose
Renal Impairment
CrCl >50 mL/min: Dose adjustment not necessary
CrCl 15-50 mL/min: 75% of regular dose
CrCl < 15 mL/min: Not studied; consider further dose reductions
Administration
Contra Indications
Hypersensitivity, pregnancy, lactation.
Precautions
Skin reactions may occur with accidental exposure; renal or hepatic disease. Periodic CBCs should be done before, during and after therapy. Increased risk of etoposide-toxicity in patients with low serum albumin. Acrylic material has been shown to crack and leak when used with undiluted etoposide inj.
Lactation: not known if excreted in breast milk, discontinue drug or do not nurse
Pregnancy-Lactation
Interactions
Synergism with other cytotoxic drugs. Caution when admin with drugs that inhibit phosphatase activity. Cyclosporin A may reduce the clearance of etoposide.
Adverse Effects
Side effects of Etoposide :
>10%
Leukopenia (60-91%),Nausea and Vomiting (30-40%),Thrombocytopenia (28-41%),Alopecia (20-90%),Anorexia (13%),Diarrhea (13%),Leukopenia (60-91%),Anemia (≤33%)
1-10%
Pancytopenia (7%),Stomatitis (6%),Hepatic toxicity (3%),Type 1 hypersensitivity (2%),Orthostatic hypotension (1-2%),Peripheral neuropathy (1-2%)
Frequency Not Defined
Malaise,Shivering,Asthenia,Fever,Mucous membrane inflammation,Hyperuricemia,Local soft tissue toxicity has been reported following extravasation; see section on IV information for extravasation management
Potentially Fatal: Severe myelosuppression, characterised by leucopaenia and thrombocytopaenia. Cardiotoxicity. Anaphylaxis.
Mechanism of Action
Etoposide is a derivative of podophyllotoxin that inhibits DNA synthesis resulting in the arrest of the cell cycle. At low doses, it inhibits cells from entering cell cycle and at high doses, cells entering mitosis are lysed.
Note
Etopa Injection manufactured by Getwell Pharmaceuticals. Its generic name is Etoposide. Etopa is availble in Nepal.
Farmaco Nepal drug index information on Etopa Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.